BioNotebook: JP Morgan week deal roundup
This article was originally published in Scrip
It's been a big week for biotech, with the annual show-and-tell that is the JP Morgan healthcare conference. West Coast editor Mandy Jackson provided Scrip with on-the-ground coverage of the week's major events, which you can read via the links at the end of this article. Meanwhile, here is a quick digest of the week's other news that may have slipped past you amid the San Francisco frenzy.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.